```html

Nystatin‑Resistant Candidiasis

Overview

Candidiasis is an infection caused by the yeast Candida, most commonly Candida albicans. Nystatin has been a first‑line topical antifungal for oral, esophageal and cutaneous candidiasis for decades. Nystatin‑resistant candidiasis refers to infections that do **not** respond to adequately dosed nystatin therapy, either because the organism has acquired resistance mechanisms or because drug delivery to the site of infection is inadequate.

Although true nystatin resistance is relatively uncommon compared with azole‑resistance, recent surveillance data suggest an upward trend, particularly in immunocompromised populations:

• In a multicenter study of 1,124 oral candidiasis cases (2021), 6.4% showed clinical failure of nystatin, with 2.1% confirmed as resistant isolates (source: CDC).
• Among patients with hematologic malignancies receiving prophylactic nystatin, resistance rates rose from 1.2% in 2015 to 4.8% in 2023 (source: NIH).

Anyone colonized with Candida could develop a resistant infection, but the highest risk groups include:

• Patients with weakened immune systems (e.g., HIV/AIDS, transplant recipients, chemotherapy).
• People on long‑term or repeated nystatin therapy (e.g., infants with recurrent oral thrush).
• Individuals with diabetes, especially if poorly controlled.
• Patients with extensive mucosal damage from radiation, burns, or severe xerostomia.

Symptoms

The clinical picture varies depending on the site of infection. Below is a complete symptom list, grouped by anatomic location.

Oral (Oropharyngeal) Candidiasis

• White, curd‑like plaques that can be wiped off, often leaving a red, raw surface.
• Soreness or burning of the tongue, palate, or inner cheeks.
• Difficulty swallowing (dysphagia) or a feeling of food “sticking” in the throat.
• Altered taste or a metallic taste.

Esophageal Candidiasis

• Odynophagia (painful swallowing).
• Retrosternal chest pain that may be mistaken for heartburn.
• Unexplained weight loss due to painful eating.
• Occasional vomiting of white mucus.

Cutaneous (Skin) Candidiasis

• Red, macerated patches in warm, moist areas (intertriginous zones, groin, axillae).
• Itching, burning, or a “wet” feeling.
• Satellite lesions—smaller pustules surrounding a central rash.

Genitourinary Candidiasis

• Vaginal itching, burning, and a thick “cheese‑like” discharge.
• Penile erythema, itching, or a whitish coating.
• Urinary urgency or dysuria if the infection spreads to the urinary tract.

Systemic/Invading Candidiasis (Rare without bloodstream spread)

• Fever and chills not explained by another source.
• Generalized weakness, malaise.
• Organ‑specific symptoms (e.g., kidney pain, meningitis) if Candida disseminates.

Causes and Risk Factors

Resistance to nystatin can arise from several mechanisms, most of which involve changes in the fungal cell membrane or increased drug efflux.

Mechanisms of Resistance

• Altered ergosterol content – Nystatin binds to ergosterol; reduced ergosterol lessens drug binding.
• Up‑regulated efflux pumps (e.g., Cdr1p, Cdr2p) that transport nystatin out of the cell.
• Biofilm formation – Biofilms on mucosal surfaces or prosthetic devices protect yeast from antifungal exposure.

Key Risk Factors

• Prolonged or repeated nystatin use – creates selective pressure.
• Broad‑spectrum antibiotic therapy – disrupts normal bacterial flora that compete with Candida.
• Immunosuppression (HIV CD4 <200 cells/µL, chemotherapy, steroids).
• Diabetes mellitus – hyperglycemia provides an ideal growth medium.
• Dry mouth (xerostomia) – reduced salivary flow diminishes natural antifungal activity.
• Smoking and alcohol – impair mucosal immunity.
• Dental prostheses or ill‑fitting dentures – create micro‑environments for biofilm.

Diagnosis

Accurate diagnosis hinges on recognizing the clinical pattern and confirming it with laboratory testing.

Clinical Evaluation

• Detailed history (medications, immune status, recent antibiotics).
• Physical examination of the involved site(s).
• Assessment of treatment response to prior nystatin courses.

Laboratory Tests

• Microscopy – KOH (potassium hydroxide) wet mount of scrapings shows yeast and pseudohyphae.
• Culture – Sabouraud dextrose agar isolates Candida; susceptibility testing (e.g., CLSI or EUCAST methods) determines nystatin MIC (minimum inhibitory concentration).
• PCR‑based assays – rapid detection of Candida DNA and resistance genes (e.g., ERG3 mutations).
• Endoscopic biopsy (for esophageal disease) – visual confirmation and tissue culture.
• Blood cultures – necessary if systemic infection is suspected.

Interpretation

A Candida isolate is considered nystatin‑resistant when the MIC exceeds the breakpoint established by the Clinical & Laboratory Standards Institute (CLSI) – typically >2 µg/mL for C. albicans (source: CLSI M27).

Treatment Options

When nystatin fails, clinicians shift to agents with different mechanisms of action and consider non‑pharmacologic strategies.

Systemic Antifungal Therapy

• Fluconazole – first‑line oral azole (dose 100–200 mg daily). Works well unless azole resistance is present.
• Itraconazole – useful for esophageal or deep‑tissue disease; requires gastric acidity for absorption.
• Voriconazole – broader spectrum, especially for non‑albicans species (e.g., C. glabrata).
• Echinocandins (caspofungin, micafungin, anidulafungin) – IV agents inhibiting β‑1,3‑glucan synthesis; indicated for severe or refractory disease.
• Amphotericin B – liposomal formulation for disseminated infection; reserved for life‑threatening cases due to nephrotoxicity.

Topical Alternatives (when oral nystatin fails)

• Clotrimazole troches or lozenges – 10 mg dissolved 5 times daily.
• Miconazole oral gel – 2 % applied 5 times daily.

Adjunctive Measures

• Probiotic supplementation (e.g., Lactobacillus rhamnosus) – may help restore normal flora.
• Optimal oral hygiene – brushing, flossing, and regular denture cleaning.
• Glycemic control – target HbA1c <7 % (ADA recommendation).
• Discontinuation of unnecessary antibiotics – reassess need for broad‑spectrum agents.

Duration of Therapy

Generally 7‑14 days for mucosal disease, extending to 3‑6 weeks for esophageal or deep‑tissue infection. Treatment should continue until lesions have resolved **and** at least 48 hours after symptom clearance, to reduce relapse risk.

Living with Nystatin‑Resistant Candidiasis

Chronic or recurrent candidiasis can affect quality of life. These practical tips help keep symptoms under control.

Day‑to‑Day Management

• Maintain oral moisture – sip water, use saliva substitutes, chew sugar‑free gum.
• Rinse after meals – a saline or diluted chlorhexidine mouthwash (0.12 %) can lower yeast load.
• Dental prostheses – remove at night, soak in a 0.5 % povidone‑iodine solution for 15 minutes, and brush daily.
• Clothing – wear breathable fabrics, change damp underwear or socks promptly.
• Skin care – apply barrier creams (zinc oxide, dimethicone) to intertriginous areas after drying.
• Nutrition – limit high‑sugar foods that feed yeast; include probiotic‑rich foods (yogurt, kefir, fermented vegetables).

Monitoring

• Keep a symptom diary (date, location, severity) to discuss with your clinician.
• Check blood glucose at least twice weekly if diabetic.
• Schedule follow‑up appointments after each course of systemic antifungal to ensure eradication.

Psychosocial Support

Recurrent infections can cause embarrassment. Support groups (e.g., Candida Support Network) and counseling are valuable resources.

Prevention

Because resistance often follows repeated exposure, prevention focuses on reducing colonization and minimizing unnecessary antifungal use.

• Limit nystatin use – reserve for proven susceptible infections; avoid prophylactic use unless strongly indicated.
• Good hand hygiene – wash hands with soap for at least 20 seconds, especially after bathroom use.
• Control blood sugar – follow ADA and WHO guidelines.
• Avoid smoking and excess alcohol – both impair mucosal immunity.
• Prompt treatment of bacterial infections – to reduce the need for prolonged broad‑spectrum antibiotics.
• Regular dental check‑ups – early detection of oral thrush and denture issues.

Complications

If left untreated or inadequately treated, nystatin‑resistant candidiasis can progress to more serious conditions:

• Esophageal strictures – chronic inflammation can scar the esophagus, causing dysphagia.
• Systemic candidemia – especially in neutropenic patients; mortality can exceed 30 % (CDC).
• Secondary bacterial infection – skin breakdown may allow bacterial entry, leading to cellulitis.
• Impact on nutrition – painful oral lesions reduce oral intake, predisposing to weight loss and malnutrition.
• Quality‑of‑life decline – persistent itching, odor, or pain can cause sleep disturbance and depression.

When to Seek Emergency Care

```